During the last European Hematology Association (EHA) congress in Madrid, there were several presentations on the treatment of newly diagnosed and relapsed multiple myeloma. These included results from phase III trials, which will again change our treatment guidelines in the near future.
(BELG J HEMATOL 2024;15(5):190–2)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
